{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:27:45Z","timestamp":1781198865006,"version":"3.54.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.cpcardiol.2022.101571","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T02:05:21Z","timestamp":1672193121000},"page":"101571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Epidemiology, Mechanisms, and Management of Atrial Fibrillation in Cardiac Amyloidosis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0244-3716","authenticated-orcid":false,"given":"Syed","family":"Bukhari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Oliveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101571_bib0001","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC Cardio Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0002","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0003","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2967\/jnumed.120.245381","article-title":"Molecular imaging of cardiac amyloidosis","volume":"61","author":"Masri","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0004","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ehf2.12308","article-title":"Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience","volume":"5","author":"Mints","year":"2018","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0005","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: transthyretin cardiac amyloid study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0007","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/CIRCULATIONAHA.120.052136","article-title":"Prevalence of atrial fibrillation and thromboembolic risk in wild-type transthyretin amyloid cardiomyopathy","volume":"143","author":"Bukhari","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0008","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1161\/STROKEAHA.121.038451","article-title":"Association between systemic amyloidosis and intracranial hemorrhage","volume":"53","author":"Chen","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0009","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ehf2.13851","article-title":"Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis","volume":"9","author":"Papathanasiou","year":"2022","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0010","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/ejhf.2566","article-title":"Systemic embolism in amyloid transthyretin cardiomyopathy","volume":"24","author":"Vilches","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0011","first-page":"168","article-title":"Trends, associations, and impact of atrial fibrillation in patients with light-chain cardiac amyloidosis","volume":"20","author":"Abe","year":"2021","journal-title":"Crit Pathw Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0012","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/13506129.2020.1810010","article-title":"Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding","volume":"28","author":"Mitrani","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0013","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.amjcard.2021.07.028","article-title":"Management strategies for atrial fibrillation and flutter in patients with transthyretin cardiac amyloidosis","volume":"157","author":"Dale","year":"2021","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0016","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0017","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0018","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0019","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.112.113233","article-title":"Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal","volume":"126","author":"Rosenberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0020","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1161\/01.CIR.0000034511.06350.DF","article-title":"Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation","volume":"106","author":"R\u00f6cken","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0021","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0022","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2650","article-title":"Atrial amyloidosis: mechanisms and clinical manifestations","author":"Vergaro","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0023","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/13506129.2018.1430027","article-title":"Reduced left atrial myocardial deformation irrespective of cavity size: a potential cause for atrial arrhythmia in hereditary transthyretin amyloidosis","volume":"25","author":"Henein","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2007.09.026","article-title":"Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation","volume":"51","author":"Casaclang-Verzosa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0025","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1046\/j.1540-8167.2004.04459.x","article-title":"Altered atrial structure begets atrial fibrillation, but how?","volume":"15","author":"Saffitz","year":"2004","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0026","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jacc.2016.10.059","article-title":"Cardiac autonomic dysfunction and incidence of atrial fibrillation: results from 20 years follow-up","volume":"69","author":"Agarwal","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0027","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0735-1097(84)80436-2","article-title":"Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities","volume":"3","author":"Falk","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0028","doi-asserted-by":"crossref","unstructured":"Chan N, Hanna M, Maurer MS. The Wiggers diagram: hemodynamic changes in cardiac amyloidosis. J Card Fail. 2022:S1071-9164(22)00580-2.https:\/\/doi.org\/10.1016\/j.cardfail.2022.06.008.","DOI":"10.1016\/j.cardfail.2022.06.008"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0029","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/thx.37.9.711","article-title":"Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine","volume":"37","author":"Griffiths","year":"1982","journal-title":"Thorax"},{"issue":"13 Pt 1","key":"10.1016\/j.cpcardiol.2022.101571_bib0030","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"issue":"13 Pt 1","key":"10.1016\/j.cpcardiol.2022.101571_bib0031","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/0002-9149(85)90996-8","article-title":"Selective binding of nifedipine to amyloid fibrils","volume":"55","author":"Gertz","year":"1985","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0032","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0033","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/0003-4819-55-6-989","article-title":"Cardiac amyloidosis. Two cases with digitalis sensitivity","volume":"55","author":"Cassidy","year":"1961","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0034","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/13506129.2018.1449744","article-title":"Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?","volume":"25","author":"Muchtar","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0035","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.hrthm.2007.07.020","article-title":"A practical guide for clinicians who treat patients with amiodarone: 2007","volume":"4","author":"Goldschlager","year":"2007","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0036","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.14082","article-title":"Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants","author":"Touboul","year":"2022","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0038","first-page":"1128","article-title":"Left atrial structure and function in cardiac amyloidosis","volume":"18","author":"Nochioka","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0039","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jcmg.2018.02.016","article-title":"Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles","volume":"12","author":"Knight","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10 Pt 1","key":"10.1016\/j.cpcardiol.2022.101571_bib0040","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/0002-9149(88)91210-6","article-title":"Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion","volume":"62","author":"Dethy","year":"1988","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0041","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9149(91)90707-R","article-title":"Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter","volume":"68","author":"Van Gelder","year":"1991","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0042","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/europace\/euz314","article-title":"Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis","volume":"22","author":"Donnellan","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0043","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/pace.13992","article-title":"Catheter ablation of atrial fibrillation in cardiac amyloidosis","volume":"43","author":"Black-Maier","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0044","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/jce.13046","article-title":"Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis","volume":"27","author":"Tan","year":"2016","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0045","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation."},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0046","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0047","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.CIR.92.2.160","article-title":"Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution","volume":"92","author":"Collins","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0048","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jacc.2020.10.057","article-title":"Persistence of left atrial appendage thrombus in patients with cardiac amyloidosis","volume":"77","author":"El-Am","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0049","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ana.10552","article-title":"Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis","volume":"53","author":"Berghoff","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0050","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3109\/13506129909007339","article-title":"Abnormalities in thrombin-antithrombin pathway in AL amyloidosis","volume":"6","author":"Gamba","year":"1999","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0051","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0052","article-title":"Effectiveness and safety of oral anticoagulants in cardiac amyloidosis: lights and shadows","author":"Di Lisi","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0053","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2022.101571_bib0054","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622004674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:05:35Z","timestamp":1758938735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622004674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0146280622004674"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101571","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology, Mechanisms, and Management of Atrial Fibrillation in Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101571"}}